{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:03:06Z","timestamp":1785153786523,"version":"3.55.0"},"reference-count":46,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016374","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:21:51Z","timestamp":1785151311000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0957-1378","authenticated-orcid":false,"given":"Osama","family":"Abed","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Lillebaelt Hospital; Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-078X","authenticated-orcid":false,"given":"Andreas","family":"Hallan","sequence":"additional","affiliation":[{"name":"Medical Department; Levanger Hospital; Levanger Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-2576","authenticated-orcid":false,"given":"Mie Micheelsen","family":"Norl\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Lillebaelt Hospital; Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2699-0041","authenticated-orcid":false,"given":"Lars","family":"Koch Hansen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Lillebaelt Hospital; Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-8549","authenticated-orcid":false,"given":"Mette","family":"Munk Lauridsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Esbjerg and Grindsted Hospital; Esbjerg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiken Thyregod","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology; Lillebaelt Hospital; Vejle Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-6572","authenticated-orcid":false,"given":"Jens","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastrointestinal Diseases; Odense University Hospital; Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD016374-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MIB.0000000000000178","article-title":"Surgical management of ulcerative colitis in the era of biologicals","volume":"21","author":"Devaraj","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10401","key":"10.1002\/14651858.CD016374-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD016374-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current pharmacotherapeutic options for the treatment of uUlcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"8","key":"10.1002\/14651858.CD016374-BIB0004|cit4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000543.pub5","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","author":"Murray","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD016374-BIB0005|cit5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000544.pub5","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Murray","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016374-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2125.1983.tb02254.x","article-title":"Kinetics of 5-aminosalicylic acid after jejunal instillation in man","volume":"16","author":"Nielsen","year":"1983","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD016374-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"89\u2013103","DOI":"10.1016\/j.ejpb.2021.07.014","article-title":"Mesalazine and inflammatory bowel disease \u2013 from well-established therapies to progress beyond the state of the art","volume":"167","author":"Veloso","year":"2021","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1002\/14651858.CD016374-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"577\u201398","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Medica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD016374-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14712598.2019.1666101","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","volume":"20","author":"Le Berre","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10.1002\/14651858.CD016374-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis","volume":"58","author":"Berends","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD016374-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"389\u201393","DOI":"10.3109\/00365528209182073","article-title":"Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease","volume":"17","author":"Nielsen","year":"1982","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD016374-BIB0012|cit12","first-page":"892\u20135","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD016374-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-118-7-199304010-00009","article-title":"Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis","volume":"118","author":"Sutherland","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD016374-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.14164","article-title":"Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis","volume":"46","author":"D'Haens","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD016374-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gut.2008.154302","article-title":"Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial","volume":"58","author":"Kruis","year":"2009","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD016374-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","article-title":"MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials","volume":"26","author":"Sandborn","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD016374-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1365-2036.2009.04117.x","article-title":"Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol","volume":"30","author":"Prantera","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD016374-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based consensus on the management of ulcerative colitis: Current management","volume":"2","author":"Travis","year":"2008","journal-title":"Journal of Crohn's and Colitis"},{"issue":"10","key":"10.1002\/14651858.CD016374-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management","volume":"6","author":"Dignass","journal-title":"Journal of Crohn's and Colitis"},{"issue":"7","key":"10.1002\/14651858.CD016374-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current Management","volume":"11","author":"Harbord","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD016374-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD016374-BIB0022|cit22","first-page":"63","volume-title":"British National Formulary, No. 67","author":"British Medical Association and the Royal Pharmaceutical Society","year":"2014"},{"key":"10.1002\/14651858.CD016374-BIB0023|cit23","first-page":"63","volume-title":"British National Formulary, No. 69","author":"British Medical Association and the Royal Pharmaceutical Society","year":"2015"},{"issue":"1","key":"10.1002\/14651858.CD016374-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2036.2003.01408.x","article-title":"Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis","volume":"17","author":"Sandborn","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD016374-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/pharmaceutics15020587","article-title":"A systematic overview of Eudragit\u00ae based copolymer for smart healthcare","volume":"15","author":"Nikam","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1002\/14651858.CD016374-BIB0026|cit26","first-page":"721","article-title":"Ethyl cellulose as a potential sustained release coating for oral pharmaceuticals","volume":"31","author":"Salib","year":"1976","journal-title":"Pharmazie"},{"key":"10.1002\/14651858.CD016374-BIB0027|cit27","unstructured":"The Danish Health Data Authority Total sale of medicines in Denmark \u2013 2019-2023 https:\/\/sundhedsdatastyrelsen.dk\/Media\/638772033697811704\/Samlet%20salg%20af%20l%C3%A6gemidler%20i%20Danmark%20fra%202019-2023.pdf"},{"key":"10.1002\/14651858.CD016374-BIB0028|cit28","unstructured":"Danish Medicines Agency Medicine Prices: Asacol https:\/\/medicinpriser.dk\/Default.aspx?id=15&vnr=148409"},{"key":"10.1002\/14651858.CD016374-BIB0029|cit29","unstructured":"Danish Medicines Agency Medicine Prices: Mesalazin \u201cOrion\u201d https:\/\/medicinpriser.dk\/Default.aspx?id=15&vnr= 420043"},{"issue":"2","key":"10.1002\/14651858.CD016374-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/flgastro-2012-100210","article-title":"Pharmacy-led switches of 5-ASA: impact on secondary care","volume":"4","author":"Healey","year":"2013","journal-title":"Frontline Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD016374-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/apt.12396","article-title":"Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse","volume":"38","author":"Robinson","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD016374-BIB0032|cit32","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Intervention s Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0033|cit33","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016374-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD016374-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing severity of disease in patients with ulcerative colitis","volume":"49","author":"Pabla","year":"2020","journal-title":"Gastroenterology Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD016374-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary international consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease.","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD016374-BIB0037|cit37","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0038|cit38","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0039|cit39","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD016374-BIB0040|cit40","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016374-BIB0042|cit42","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0044|cit44","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016374-BIB0045|cit45","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016374-BIB0046|cit46","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:21:56Z","timestamp":1785151316000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016374"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016374","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}